Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Research output: Contribution to journalArticle

Abstract

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

Details

Authors
  • Pia Burman
  • Britt Edén-Engström
  • Bertil Ekman
  • F Anders Karlsson
  • Erik Schwarcz
  • Jeanette Wahlberg
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
Original languageEnglish
Pages (from-to)17-24
JournalEuropean Journal of Endocrinology
Volume174
Issue number1
Publication statusPublished - 2016
Publication categoryResearch
Peer-reviewedYes